Previous 10 | Next 10 |
Gainers: Aurora Cannabis (ACB) +75%.Sundial Growers (SNDL) +57%.Modine Manufacturing (MOD) +41%.Akerna (KERN) +40%.Tilray (TLRY) +40%.Cooper-Standard (CPS) +35%.Mogo (MOGO) +32%.OrganiGram (OGI) +29%.Glu Mobile (GLUU) +28%.FTS International (FTSI) +21%.Losers: Assembly Bioscien...
Gainers: Aurora Cannabis (ACB) +82%, Sundial Growers (SNDL) +69%, Tilray (TLRY) +36%, OrganiGram Holdings Inc. (OGI) +30%, MEDNAX (MD) +19%.Losers: Assembly Biosciences (ASMB) -69%, Global Blood Therapeutics (GBT) -35%, AcelRx Pharmaceuti...
Assembly Biosciences (ASMB) -55% on Q3 earnings release.Global Blood Therapeutics (GBT) -32% on Q3 earnings release.Epizyme (EPZM) -23% on Q3 earnings release.Marin Software (MRIN) -14% on Q3 earnings release.Hall of Fame Resort & Entertainment (HOF...
Assembly Biosciences (ASMB) craters 58% in premarket in reaction to vebicorvir data from Phase 2 extension (211) study, which failed to achieve meaningful sustained virologic response ((SVR)) rates in patients with chronic HBV infection. 39 of 41 patien...
Gainers: [[FTSI]] +80%. [[AVNW]] +17.5%. [[AGS]] +16%. [[GLUU]] +15.8%. [[CNDT]] +9.2%.Losers: [[ASMB]] -38.6%. [[GBT]] -30.4%. [[AAOI]] -20.7%. [[MRIN]] -14%. [[NVRO]] -10%. For further details see: GLUU, AAOI, CNDT and GBT among after-hours movers
Assembly Biosciences (ASMB): Q3 GAAP EPS of -$0.09 beats by $0.69.Revenue of $34.61M (+718.2% Y/Y) beats by $28.17M.Shares -24.84%.Press Release For further details see: Assembly Biosciences EPS beats by $0.69, beats on revenue
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today reported financial results...
- HBV field’s first c ore i nhibitor combination study to assess off-treatment response has not achieve d a meaningful rate of sustained virologic response - - Vebicorvir Phase 3 registrational pr...
- Four posters, including two late breaking, will include new clinical and preclinical data on Assembly Bio ’s hepatitis B virus ( HBV ) core inhibitor portfolio SOUTH SAN FRANCISCO, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- A...
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the appointment ...
News, Short Squeeze, Breakout and More Instantly...
Assembly Biosciences Inc. Company Name:
ASMB Stock Symbol:
NASDAQ Market:
Assembly Biosciences Inc. Website:
2024-07-16 14:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented – – Poster presentation highlights key preclinical data from ABI-5366 supporting its entry into ongoing Phase 1a/b clinical ...
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1b trial of ABI-4334, a nex...